This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research
Risk factors of cytomegalovirus infection or reactivation in ulcerative colitis patients
Hao Wang
Tianjin Medical University General Hospital, Tianjin General Surgery Institute
Corresponding Author
ORCiD: https://orcid.org/0000-0001-9990-2714
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
To identify the risk factors for cytomegalovirus (CMV)infection or reactivation in ulcerative colitis (UC) patients.
Method
PubMed, Cochrane Library, EMBASE, Web of Science and CNKI were retrieved from the inception of electronic databases to February 2020. All analyses were performed using Stata/SE 15.1 version (StataCorp).
Result
22 papers were included. There was significant difference in severe UC (OR = 1.465, 95% CI: 1.107 to 1.939, P = 0.008), pancolitis (OR = 2.108, 95% CI: 1.586 to 2.800, P = 0.0001), age of onset (MD = 6.212, 95% CI: 2.552 to 9.971, P = 0.001), glucocorticoid (OR = 4.175, 95% CI: 3.076 to 5.666, P = 0.001), immunosuppressant (OR = 2.038, 95% CI: 1.259 to 3.301, P = 0.004), 5-ASA (OR = 0.674, 95% CI: 0.492 to 0.924, P = 0.014). However, no significant difference was detected in disease duration, infliximab.
Conclusion
Severe UC, pancolitis, glucocorticoid, immunosuppressive therapy and age of onset are the risk factors of CMV infection or reactivation in UC patients, we should closely monitor if UC patients with the above indicators and give timely symptomatic treatment to prevent the disease from worsening.
Keywords
ulcerative colitis, cytomegalovirus, risk factor
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Figure 11
This is a list of supplementary files associated with this preprint. Click to download.
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 20 May, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Translational Medicine
Learn more about our company.
This is a preprint. It has not completed peer review.
Research
Risk factors of cytomegalovirus infection or reactivation in ulcerative colitis patients
Hao Wang
Tianjin Medical University General Hospital, Tianjin General Surgery Institute
Corresponding Author
ORCiD: https://orcid.org/0000-0001-9990-2714
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 20 May, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Translational Medicine
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
To identify the risk factors for cytomegalovirus (CMV)infection or reactivation in ulcerative colitis (UC) patients.
Method
PubMed, Cochrane Library, EMBASE, Web of Science and CNKI were retrieved from the inception of electronic databases to February 2020. All analyses were performed using Stata/SE 15.1 version (StataCorp).
Result
22 papers were included. There was significant difference in severe UC (OR = 1.465, 95% CI: 1.107 to 1.939, P = 0.008), pancolitis (OR = 2.108, 95% CI: 1.586 to 2.800, P = 0.0001), age of onset (MD = 6.212, 95% CI: 2.552 to 9.971, P = 0.001), glucocorticoid (OR = 4.175, 95% CI: 3.076 to 5.666, P = 0.001), immunosuppressant (OR = 2.038, 95% CI: 1.259 to 3.301, P = 0.004), 5-ASA (OR = 0.674, 95% CI: 0.492 to 0.924, P = 0.014). However, no significant difference was detected in disease duration, infliximab.
Conclusion
Severe UC, pancolitis, glucocorticoid, immunosuppressive therapy and age of onset are the risk factors of CMV infection or reactivation in UC patients, we should closely monitor if UC patients with the above indicators and give timely symptomatic treatment to prevent the disease from worsening.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Figure 11